Status:
UNKNOWN
Esketamine Combined With Pregabalin on CPSP in Spinal Patients.
Lead Sponsor:
Beijing Tiantan Hospital
Conditions:
Esketamine
Pregabaline
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
PHASE3
Brief Summary
Chronic postsurgical pain has become one of the most common complications of surgery. The quality of life will be impacted once the postsurgical patients are combined with persistent pain. What's more...
Eligibility Criteria
Inclusion
- Patient undergoing elective primary spinal tumor surgery;
- Ages between 18 and 65 years old;
- American Society of Anaesthesiology (ASA) status I-III;
- Signed informed consent.
Exclusion
- Previous adverse reaction to ketamine, s-ketamine or pregabalin;
- Patients with a diagnosed history of severe chronic pain;
- Patients with long-term analgesic treatment(gabapentin/opioids/ketamine);
- Patients with aphasia or inability to cooperate with the pain assessments;
- Known sever insufficiency of vitals(such as heart failure/renal dysfunction/hepatic failure);
- Patients with a diagnosed history of psychiatric disorder;
- Patients treated with gabapentin/pregabalin in the last three months;
- Drug abuse;
- Body mass index (BMI) \> 35 kg/m2 ;
- Pregnancy or lactation.
Key Trial Info
Start Date :
November 10 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2024
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT06117917
Start Date
November 10 2023
End Date
June 30 2024
Last Update
November 7 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Tiantan Hospital
Beijing, China, 100070